Capmatinib
136 interactions 289 cited referencesCapmatinib is used to treat a certain type of non-small cell lung cancer (NSCLC) that has spread to other parts of the body. Capmatinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread… Read the full Capmatinib drug information page →
Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →
Major
Capmatinib Voriconazole Vfend Increased tyrosine kinase inhibitors exposure Details Capmatinib Voxilaprevir Increased P-gp substrate exposure and an increased risk of increased adverse reactions Details Capmatinib Warfarin Coumadin Increased warfarin exposure and an increased INR Details Capmatinib Cyclosporine Injection Atopica Increased cycloSPORINE exposure Details Capmatinib Cyclosporine Ophthalmic Cequa Increased cycloSPORINE exposure Details Capmatinib Dabigatran Pradaxa® Increased dabigatran exposure and an increased risk of bleeding Details Capmatinib Irinotecan Injection Camptosar Increased BCRP substrate exposure and an increased risk of adverse reactions Details Capmatinib Letermovir Injection Prevymis Increased CYP3A substrate exposure Details Capmatinib Methotrexate Injection Abitrexate® Increased BCRP substrate exposure and an increased risk of adverse reactions Details Capmatinib Morphine Injection Astramorph® PF Increased morphine exposure and an increased risk of morphine-related adverse effects (hypotension, respiratory depression, profou... Details Capmatinib Nafcillin Injection Unipen® Injection Decreased capmatinib exposure and reduction of antitumor activity DetailsModerate
Capmatinib Artemether Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Capmatinib Kratom Increased CYP3A substrate exposure Details Capmatinib Levothyroxine Ermeza Increased risk of hypothyroidism Details Capmatinib Mavacamten Camzyos Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Capmatinib Rilzabrutinib Wayrilz Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions DetailsNo interactions on this page match that filter — try the next page or clear the filter.
Check another drug
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist